glp-1 georgia woman part of lawsuit claiming link between weight loss drugs and blindness Georgia Poison Center reports surge

Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial)

The risks of arrhythmias and their subtypes in published high-quality CVOTs of GLP-1RA drug therapy in patients with type 2 diabetes up to March 1, 2022, were therefore extracted, based on this, we also conducted a systematic review and meta-analysis

K., Lysiuk, R., Antonyak, H., Noor, S., Akram, M., Smetanina, K., Piscopo, S., Upyr, T., & Peana, M

Dont stop taking a prescribed medication without first consulting with your doctor

doi:10.1245/s10434-018-6660-x

Efficacy magnitude Clinical trials show GLP-1 agonists produce substantial HbA1c reductions (typically 1.01.5% depending on agent and dose) and weight loss (515% of body weight with higher doses)